JP2002518050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002518050A5 JP2002518050A5 JP2000556035A JP2000556035A JP2002518050A5 JP 2002518050 A5 JP2002518050 A5 JP 2002518050A5 JP 2000556035 A JP2000556035 A JP 2000556035A JP 2000556035 A JP2000556035 A JP 2000556035A JP 2002518050 A5 JP2002518050 A5 JP 2002518050A5
- Authority
- JP
- Japan
- Prior art keywords
- structural protein
- mutation
- protein according
- nucleic acid
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710172711 Structural protein Proteins 0.000 description 27
- 230000035772 mutation Effects 0.000 description 18
- 238000000034 method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 230000037431 insertion Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000003446 ligand Substances 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19827457A DE19827457C1 (de) | 1998-06-19 | 1998-06-19 | Strukturprotein von AAV, seine Herstellung und Verwendung |
| DE19827457.2 | 1998-06-19 | ||
| PCT/EP1999/004288 WO1999067393A2 (de) | 1998-06-19 | 1999-06-21 | Strukturprotein von aav, seine herstellung und verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002518050A JP2002518050A (ja) | 2002-06-25 |
| JP2002518050A5 true JP2002518050A5 (https=) | 2006-08-03 |
| JP4652570B2 JP4652570B2 (ja) | 2011-03-16 |
Family
ID=7871464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000556035A Expired - Fee Related JP4652570B2 (ja) | 1998-06-19 | 1999-06-21 | Ａａｖの構造タンパク質、その製造及び用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20070238684A1 (https=) |
| EP (3) | EP1088075B1 (https=) |
| JP (1) | JP4652570B2 (https=) |
| AT (2) | ATE338821T1 (https=) |
| AU (1) | AU765330B2 (https=) |
| CA (1) | CA2332115C (https=) |
| DE (3) | DE19827457C1 (https=) |
| DK (1) | DK1783225T3 (https=) |
| ES (2) | ES2352666T3 (https=) |
| WO (1) | WO1999067393A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
| DE69929232T2 (de) | 1998-10-21 | 2006-08-31 | The United States Government As Represented By The Department Of Health And Human Services | Virusähnliche partikel zur induktion von autoantikörpern |
| DE19849643A1 (de) * | 1998-10-29 | 2000-05-04 | Deutsches Krebsforsch | An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer |
| US6759237B1 (en) | 1998-11-05 | 2004-07-06 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US7314912B1 (en) | 1999-06-21 | 2008-01-01 | Medigene Aktiengesellschaft | AAv scleroprotein, production and use thereof |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| DE19933719A1 (de) * | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
| US9441244B2 (en) * | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| JP5136766B2 (ja) | 2004-12-15 | 2013-02-06 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | キメラベクター |
| EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP3003391B1 (en) | 2013-05-31 | 2021-09-22 | The Regents of The University of California | Adeno-associated virus variants and methods of use thereof |
| EP3800191B1 (en) | 2014-03-17 | 2025-08-20 | Adverum Biotechnologies, Inc. | Compositions and methods for enhanced gene expression in cone cells |
| US11021519B2 (en) | 2015-03-02 | 2021-06-01 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| JP6836999B2 (ja) | 2015-03-24 | 2021-03-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | アデノ随伴ウイルス変異体及びその使用方法 |
| AU2017302013B2 (en) | 2016-07-29 | 2022-05-26 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| CA3040179A1 (en) | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| CA3053154A1 (en) | 2017-06-30 | 2019-01-03 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsids and methods of use thereof |
| JP2020534788A (ja) | 2017-08-28 | 2020-12-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルスカプシド変異体及びその使用方法 |
| BR112020014093A2 (pt) * | 2018-01-11 | 2020-12-01 | Chameleon Biosciences, Inc. | vetores imuno-evasivos e uso para terapia gênica |
| US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
| CN113728108A (zh) | 2019-02-15 | 2021-11-30 | 桑格摩生物治疗股份有限公司 | 用于生产重组aav的组合物和方法 |
| KR102917057B1 (ko) * | 2019-04-24 | 2026-01-23 | 다카라 바이오 가부시키가이샤 | 뇌에 지향성을 가지는 aav 돌연변이체 |
| KR20220039725A (ko) * | 2019-07-02 | 2022-03-29 | 트러스티즈 오브 터프츠 칼리지 | 작용제의 세포 및 조직으로의 전달을 위한 신규 펩티드, 조성물 및 방법 |
| RU2751592C2 (ru) * | 2019-08-22 | 2021-07-15 | Общество С Ограниченной Ответственностью "Анабион" | Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе |
| AR126840A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta |
| AR126839A1 (es) * | 2021-08-20 | 2023-11-22 | Llc «Anabion» | Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta |
| CN118480100B (zh) * | 2023-09-20 | 2025-04-04 | 广州派真生物技术有限公司 | 腺相关病毒突变体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0567578A1 (en) * | 1991-01-25 | 1993-11-03 | The Regents Of The University Of Minnesota | Laminin a chain domain vi polypeptides |
| FR2716893B1 (fr) | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
| US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| EP0927044A4 (en) * | 1996-04-16 | 1999-09-08 | Immusol Inc | DEFINED TARGET VIRAL VECTORS |
| US20010031463A1 (en) * | 1997-09-02 | 2001-10-18 | Jurgen Kleinschmidt | Method for purifying and concentrating AAV-2 and antigen portions thereof |
| DE19827457C1 (de) * | 1998-06-19 | 2000-03-02 | Medigene Ag | Strukturprotein von AAV, seine Herstellung und Verwendung |
| AU780231B2 (en) * | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| US7749492B2 (en) * | 2001-01-05 | 2010-07-06 | Nationwide Children's Hospital, Inc. | AAV vectors and methods |
| WO2002053703A2 (en) * | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| EP1456383B1 (en) * | 2001-12-21 | 2014-03-12 | Medigene AG | A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism |
-
1998
- 1998-06-19 DE DE19827457A patent/DE19827457C1/de not_active Expired - Fee Related
-
1999
- 1999-06-21 DE DE59915205T patent/DE59915205D1/de not_active Expired - Lifetime
- 1999-06-21 ES ES06018532T patent/ES2352666T3/es not_active Expired - Lifetime
- 1999-06-21 EP EP99929292A patent/EP1088075B1/de not_active Expired - Lifetime
- 1999-06-21 EP EP06018532A patent/EP1783225B1/de not_active Expired - Lifetime
- 1999-06-21 ES ES99929292T patent/ES2273498T3/es not_active Expired - Lifetime
- 1999-06-21 AT AT99929292T patent/ATE338821T1/de not_active IP Right Cessation
- 1999-06-21 DK DK06018532.9T patent/DK1783225T3/da active
- 1999-06-21 AT AT06018532T patent/ATE481490T1/de active
- 1999-06-21 EP EP06018533A patent/EP1783226A1/de not_active Withdrawn
- 1999-06-21 CA CA2332115A patent/CA2332115C/en not_active Expired - Fee Related
- 1999-06-21 WO PCT/EP1999/004288 patent/WO1999067393A2/de not_active Ceased
- 1999-06-21 DE DE59913833T patent/DE59913833D1/de not_active Expired - Lifetime
- 1999-06-21 AU AU46141/99A patent/AU765330B2/en not_active Ceased
- 1999-06-21 JP JP2000556035A patent/JP4652570B2/ja not_active Expired - Fee Related
-
2006
- 2006-12-28 US US11/647,687 patent/US20070238684A1/en not_active Abandoned
-
2009
- 2009-12-01 US US12/628,867 patent/US20110052617A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002518050A5 (https=) | ||
| CA2332115A1 (en) | Aav structural protein, its preparation and use | |
| CA2379220A1 (en) | Structural protein of adeno-associated virus with modified antigenicity, its production and its use | |
| US12534717B2 (en) | AAV capsid proteins for nucleic acid transfer | |
| US7172893B2 (en) | Virus vectors and methods of making and administering the same | |
| JP7393766B2 (ja) | 抗体回避ウイルスベクターのための方法および組成物 | |
| EP1198580B1 (de) | Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften | |
| AU762220B2 (en) | AAV5 vector and uses thereof | |
| JP2003505032A5 (https=) | ||
| US7314912B1 (en) | AAv scleroprotein, production and use thereof | |
| EP1228234A2 (en) | Production of chimeric capsid vectors | |
| JP2022542829A5 (https=) | ||
| Nambiar | Isolation and Characterization of Novel Adeno-Associated Viruses for the Advancement of Gene Therapy | |
| WO2024163870A1 (en) | Development of generation z (genz) single-stranded aav serotype vectors | |
| WO2025235682A1 (en) | Peptides targeting tfrc for blood-brain barrier crossing | |
| AU771545B2 (en) | AAV4 vector and uses thereof | |
| CN118324853A (zh) | 腺相关病毒突变体及其应用 | |
| Broekman et al. | AAV2/1-2, AAV2/1-8, and AAV2/2-8 mosaic vectors display enhanced transduction of neuronal cells in culture and in vivo | |
| HK1236040A1 (en) | New avv capsid proteins for nucleic acid transfer |